Biogen (BIIB) PT Raised to $320 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Biogen (BIIB), Eisai Highlight Detailed Results from Phase II Clinical Study of Elenbecestat at AAIC 2018
July 25, 2018 10:38 AM EDTEisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) at the Alzheimers Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. This poster presentation was accepted as a Late Breaking Abstract for AAIC (Poster No.: P4-389).
Study 202 (ClinicalTrials.gov identifier NCT02322021) is a multicenter, randomized, double-blind, placebo-controlled parallel-group 18-month Phase II clinical study, conducted in the United States in patients with... More
Biogen (BIIB) PT Raised to $392 at Morgan Stanley
July 25, 2018 7:46 AM EDTMorgan Stanley raised its price target on Biogen (NASDAQ: BIIB) to $392.00 (from $366.00) while maintaining a Overweight rating.
... MoreBiogen (BIIB) PT Raised to $357 at RBC Capital
July 25, 2018 7:44 AM EDTRBC Capital raised its price target on Biogen (NASDAQ: BIIB) to $357.00 (from $349.00) while maintaining a Sector Perform rating.
Analyst Brian Abraham said the solid quarter with guidance raise should help keep enthusiasm high for BIIB following recent de-risking of key Alzheimer's portfolio.
... MoreBiogen (BIIB) PT Raised to $348 at Baird
July 25, 2018 6:40 AM EDTBaird raised its price target on Biogen (NASDAQ: BIIB) to $348.00 (from $323.00) while maintaining a Neutral rating.
Analyst Brian Skorney commented, "Biogen reported in-line revenues of $3.4B and EPS of $5.80, beating consensus at $5.21. A return for growth for Spinraza and solid performance... More
Biogen (BIIB) PT Raised to $445 at JPMorgan
July 24, 2018 1:55 PM EDTJPMorgan raised its price target on Biogen (NASDAQ: BIIB) to $445.00 (from $400.00) while maintaining a Overweight rating.
Analyst Cory Kasimov remains positive on the company following a strong beat and raise in Q2. The analyst notes the resilience of the core portfolio and... More
Biogen (BIIB) Tops Q2 EPS by 56c, FY Guidance Tops Consensus
July 24, 2018 6:37 AM EDT(Updated - July 24, 2018 6:39 AM EDT)
Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.80, $0.56 better than the analyst estimate of $5.24. Revenue for the quarter came in at $3.36 billion versus the consensus estimate of $3.26 billion.
GUIDANCE:
Biogen sees FY EPS of $24.90-$25.50 vs... More
